PrOD (ombitasvir/paritaprevir/ritonavir plus dasabuvir) for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis (PIVOTAL).
The study will enroll people who will receive PrOD to treat hepatitis C genotype 1 subtype 1b who are receiving hemodialysis. The treatment period will be 12 weeks.
To view the entire study, click here
This is an investigational study of two new drugs being tested to treat hepatitis C genotypes 1 through 6 in people who had received a liver transplant or kidney transplant (post-transplant liver or kidney).
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
To read the entire clinical trial description, click here…